A Phase I Dose Escalation Trial of Gemcitabine with Radiotherapy for Breast Cancer in the Treatment of Unresectable Chest Wall Recurrences
dc.contributor.author | Suh, W. Warren | en_US |
dc.contributor.author | Schott, Anne F. | en_US |
dc.contributor.author | Hayman, James A. | en_US |
dc.contributor.author | Schipper, Matthew J. | en_US |
dc.contributor.author | Shewach, Donna S. | en_US |
dc.contributor.author | Pierce, Lori J. | en_US |
dc.date.accessioned | 2010-06-01T22:35:09Z | |
dc.date.available | 2010-06-01T22:35:09Z | |
dc.date.issued | 2004-05 | en_US |
dc.identifier.citation | Suh, W. Warren; Schott, Anne F.; Hayman, James A.; Schipper, Matthew J.; Shewach, Donna S.; Pierce, Lori J. (2004). "A Phase I Dose Escalation Trial of Gemcitabine with Radiotherapy for Breast Cancer in the Treatment of Unresectable Chest Wall Recurrences." The Breast Journal 10(3): 204-210. <http://hdl.handle.net/2027.42/75565> | en_US |
dc.identifier.issn | 1075-122X | en_US |
dc.identifier.issn | 1524-4741 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/75565 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15125746&dopt=citation | en_US |
dc.description.abstract | The purpose of this study was to determine the maximum tolerated dose (MTD) of gemcitabine when given concurrently with standard radiotherapy for the treatment of chest wall recurrences, and to compare actuarial rates of local-regional control with those achieved in historical controls. Patients with unresectable chest wall recurrences were enrolled in a phase I trial of concurrent gemcitabine and radiotherapy. Gemcitabine was increased at 150 mg/m 2 /week increments, starting at 300 mg/m 2 /week. Radiotherapy was delivered to the chest wall and regional nodes to a total of 60 to 70 Gy in 2 Gy daily fractions. Treatment toxicity was assessed and a comparison of treatment outcome was performed between study patients and historical groups treated with either radiotherapy alone or excision followed by radiotherapy. The dose-limiting toxicities of neutropenia and thrombocytopenia occurred at the second planned dose of 450 mg/m 2 /week after accrual of only six patients, resulting in a MTD of 300 mg/m 2 /week. Myelosuppression and skin desquamation were commonly observed. Actuarial rates of local-regional control were 100%, 50%, and 90% at 2 years for the gemcitabine with radiotherapy, radiotherapy alone, and excision followed by radiotherapy groups, respectively ( p = 0.105). The difference among the Kaplan–Meier curves for overall local-regional control was statistically significant at p = 0.007 in favor of combined gemcitabine and radiotherapy. The MTD of gemcitabine is 300 mg/m 2 /week when gemcitabine is delivered concurrently with radiotherapy for unresectable chest wall failures. This novel approach suggests excellent local-regional control when compared to historical controls. A phase II trial is warranted. | en_US |
dc.format.extent | 115794 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Science Inc | en_US |
dc.rights | © 2004 Blackwell Publishing, Inc. | en_US |
dc.subject.other | Breast Cancer | en_US |
dc.subject.other | Chest Wall Failure | en_US |
dc.subject.other | Gemcitabine | en_US |
dc.subject.other | Mastectomy | en_US |
dc.subject.other | Radiotherapy | en_US |
dc.title | A Phase I Dose Escalation Trial of Gemcitabine with Radiotherapy for Breast Cancer in the Treatment of Unresectable Chest Wall Recurrences | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Obstetrics and Gynecology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Pharmacology, University of Michigan, and | en_US |
dc.contributor.affiliationum | Biostatistics Core, University of Michigan Cancer Center, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | * Radiation Oncology, | en_US |
dc.contributor.affiliationother | Internal Medicine, and | en_US |
dc.identifier.pmid | 15125746 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/75565/1/j.1075-122X.2004.21305.x.pdf | |
dc.identifier.doi | 10.1111/j.1075-122X.2004.21305.x | en_US |
dc.identifier.source | The Breast Journal | en_US |
dc.identifier.citedreference | Deck KB, Kern WH. Local recurrence of breast cancer. Arch Surg 1976; 111: 323 – 25. | en_US |
dc.identifier.citedreference | Fisher B, Redmond C, Poisson R, et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without radiation in the treatment of breast cancer. N Engl J Med 1989; 320: 822 – 28. | en_US |
dc.identifier.citedreference | Crowe JP Jr, Gordon NH, Antunez AR, et al. Local-regional breast cancer recurrence following mastectomy. Arch Surg 1991; 126: 429 – 32. | en_US |
dc.identifier.citedreference | Aberizk WJ, Silver B, Henderson IC, et al. The use of radiotherapy for treatment of isolated locoregional recurrence of breast carcinoma after mastectomy. Cancer 1986; 58: 1214 – 18. | en_US |
dc.identifier.citedreference | Bedwinek JM, Lee J, Fineberg B, et al. Prognostic indicators in patients with isolated local-regional recurrence of breast cancer. Cancer 1981; 47: 2232 – 35. | en_US |
dc.identifier.citedreference | Schwaibold F, Fowble BL, Solin LJ, et al. The results of radiation therapy for isolated local regional recurrence after mastectomy. Int J Radiat Oncol Biol Phys 1991; 21: 299 – 310. | en_US |
dc.identifier.citedreference | Stadler B, Kogelnik HD. Local control and outcome of patients irradiated for isolated chest wall recurrences of breast cancer. Radiother Oncol 1987; 8: 105 – 11. | en_US |
dc.identifier.citedreference | Halverson KJ, Perez CA, Kuske RR, et al. Isolated local-regional recurrence of breast cancer following mastectomy: radiotherapeutic management. Int J Radiat Oncol Biol Phys 1990; 19: 851 – 58. | en_US |
dc.identifier.citedreference | Bedwinek JM, Fineberg B, Lee J, et al. Analysis of failures following local treatment of isolated local-regional recurrence of breast cancer. Int J Radiat Oncol Biol Phys 1981; 7: 581 – 85. | en_US |
dc.identifier.citedreference | Lund B, Kristjansen PEG, Hansen HH. Clinical and preclinical activity of 2′,2′-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev 1993; 19: 45 – 55. | en_US |
dc.identifier.citedreference | Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995; 13: 2731 – 36. | en_US |
dc.identifier.citedreference | Shewach DS, Hahn TM, Chang E, et al. Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 1994; 54: 3218 – 23. | en_US |
dc.identifier.citedreference | McGinn CJ, Shewach DS, Lawrence TS. Radiosensitizing nucleosides. J Natl Cancer Inst 1997; 88: 1193 – 203. | en_US |
dc.identifier.citedreference | Robinson WR, Shewach DS. Radiosensitization by gemcitabine in p53 wild-type and mutant MCF-7 breast carcinoma cell lines. Clin Cancer Res 2001; 7: 2581 – 89. | en_US |
dc.identifier.citedreference | Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9: 491 – 98. | en_US |
dc.identifier.citedreference | Gruenwald R, Kantarjian H, Keating MJ, et al. Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycitidine (gemcitabine) administration in leukemia. Cancer Res 1990; 50: 6823 – 26. | en_US |
dc.identifier.citedreference | Lawrence TS, Eisbruch A, Shewach DS. Gemcitabine-mediated radiosensitization. Semin Oncol 1997; 24 (2 Suppl 7): S7 - 24–S7-28. | en_US |
dc.identifier.citedreference | Eisbruch A, Shewach DS, Bradford CR, et al. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study. J Clin Oncol 2001; 19: 792 – 99. | en_US |
dc.identifier.citedreference | Pierce LJ, Strawderman MH, Douglas KR, et al. Conservative surgery and radiotherapy for early-stage breast cancer using a lung density correction: the University of Michigan experience. Int J Radiat Oncol Biol Phys 1997; 39: 921 – 28. | en_US |
dc.identifier.citedreference | Bedwinek J. Natural history and management of isolated local-regional recurrence following mastectomy. Semin Radiat Oncol 1994; 4: 260 – 69. | en_US |
dc.identifier.citedreference | McGinn CJ, Zalupski MM, Shureiqi I, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2001; 19: 4202 – 8. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.